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of novel drugs to patients and fosters divergence in reimbursement status. The 
objectives were to identify differences in REA by EU-HTA agencies, discuss the 
impact of this variation on time to patient access and assess the potential benefits 
of a centralized REA. Methods: Differences in clinical assessment across EU-HTA 
bodies were analysed for selected EMA approved Novartis drugs (internal data and 
structured telephonic interviews with Novartis Country Pharma Organisations 
(CPOs) and drugs marketed by other companies (literature review). Results: 
Differences in acceptance of comparators, subgroups and end-points were seen 
in REA across countries. Although fingolimod, secured wide reimbursement in EU 
for Relapsing-Remitting Multiple Sclerosis (RRMS), HTA bodies differed in their 
end-points’ acceptance. Example, UK accepted annual relapse rate, disability pro-
gression and MRI-lesions, while Germany didn’t accept the latter as end-point. 
Variations were seen in countries’ requirements for additional analysis to support 
REA. Example, Germany granted a ‘small additional benefit’ rating for Rapidly 
Evolving Severe RRMS subgroup based on indirect comparison, while, even an 
additional mixed treatment comparison couldn’t support REA for this subgroup in 
UK. Amongst non-Novartis drugs; pertuzumab review by IQWIG and GBA resulted 
in different end-point acceptance, with negative and restricted access recom-
mendation, respectively. For sofosbuvir, HTA bodies differed from EMA label and 
saw clinical value only in some patient subgroups. Example, IQWIG recommended 
the drug for only HCV genotype-2 whereas ZIN (Netherlands) recommended it for 
genotype-1 and 4. CPOs’ survey indicated that centralized EU-REA could reduce 
time to patient access (by ~3-4 months), through avoiding repetitive clinical 
evaluation and saving time on pricing/reimbursement pathway. ConClusions: 
Harmonized REA has the potential to reduce delay in patient access, strengthen 
the equity of care and increase predictability of expectations from pharmaceutical 
companies’ research programs.
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objeCtives: We aimed to present the characteristics and challenges of the external 
reference pricing (ERP) from the perspective of Slovenia. Methods: The literature 
search was made for the information on ERP in countries included in the Slovenian 
country basket and countries that refer Slovenia. The data on characteristics of the 
ERP such as country basket composition, calculation of the reference price, scope 
of medicines, type of comparable price and use of the ERP as main or supportive 
criterion were taken into account. Results: Slovenia defines medicine prices based 
on the prices in Austria, Germany and France, while 17 countries refer Slovenia. 
Slovenia’s greatest potential impact concerns the medicine prices in Croatia, Bosnia, 
Serbia and Portugal that refer only three countries. Their calculation method is an 
average price of reference countries, indicating that the role of Slovenia is not as 
large as it could be if the calculation method was the lowest price or the average of 
lowest three prices in reference countries. However, Slovenia does not have a greater 
role in countries calculating reference price as the lowest price or the average of 
the three lowest prices, while most of those countries refer 20 or more countries 
and Slovenia is not necessary the country with the lowest medicine price. The 
ERP represents a special challenge for countries as Slovenia that do not represent 
a large medicines market and try to reduce medicine costs to a greater extent 
than others with potential risk of medicines withdrawal. Slovenia does not have 
a direct impact on medicine prices in countries using ERP as supportive criterion. 
Further, Slovenia and Austria refer each other, representing an overlapping connec-
tion. ConClusions: The small pharmaceutical market and potentially large impact 
on the prices of medicines in other countries places Slovenia in a special position.
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objeCtives: This study appraised the health professionals and managers’ value 
judgments in Brazilian HTA process, through a new method of research that 
addresses clinical scenarios to simulate real world dilemmas and support budget 
allocation. The decisions should be made under clinical and epidemiological aspects, 
and, also, economic, social, ethical and cultural factors. The main objective was to 
evaluate how these factors have influenced the decision makers in HTA resources 
allocation. We agreed to call this model by Decision Making Clinical Scenarios 
(DMCS). Methods: This study was conducted through a decision making ques-
tionnaire with four clinical scenarios involving HTA. These scenarios introduced 
issues involving value judgments, preferences and structuring choices, considering 
a severe budget restraint. The presented trade-offs were related to health policies, 
such as budget impact, sources of funding, eligible patients, technology charac-
teristics and disease epidemiology. Results: The results showed a conservative 
trend. In all three scenarios involving some form of technological incorporation, the 
most chosen option was to avoid incorporation. Alternatives of funding, as reduc-
tion/extinction of current healthcare programs and creation of a new tax, were not 
accepted as solutions. In budget allocation between prevention and treatment pro-
grams, respondents were suited to a preventive long-term strategy. ConClusions: 
The scenarios have been shown understandable. The absolute scarcity of resources 
clearly influenced the results. In search of a paradigm for decision making, most of 
respondents prioritized to save resources, instead of incorporating the technologies. 
We concluded that managers are not guided only by clinical benefit of a decision. 
They valorized the importance of funding mechanisms and budget control that 
enable incorporation, considering economic, social, ethical, and structural aspects. 
This study model seems to be useful to evaluate the trends of conduct of decision 
makers. This model can be used in further researches, bringing different factors and 
criteria into discussion, through clinical real world situations.
tion (n= 7 drugs). For each claim the source of payment and price difference, where 
applicable, were deduced from the recorded expenditure. Trends, including costs to 
the HSE, were monitored over time. The impact of time since policy introduction and 
price difference magnitude on DNS likelihood (HSE payment) were explored using 
logistic regression. Results: Overall, generic drug dispensing rose from 79% to 92% at 
six months following policy introduction. However, within premium-priced products 
dispensed (8% overall), the proportion of DNS increased from 15% to 39%. Time since 
policy introduction and magnitude of price difference were both positive predic-
tors of DNS (versus patient payment) (p< 0.001). ConClusions: GS/RP successfully 
increased generic dispensing. However, estimated DNS rates increased significantly in 
the first 6 months, incurring additional costs to the HSE, and were predicted by higher 
potential costs to the patient. These trends suggest that the burden of co-payment 
within GS/RP is increasingly being passed to the health service. With continual roll-
out of GS/RP, interventions may be required to ensure DNS occurrences appropriately 
reflect medical need.
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objeCtives: The appropriate use of drugs including antibiotics is crucial towards 
achieving better quality of life. The aim of this study was to assess the prescrib-
ing practices and antibiotic use patterns in the Accident and Emergency (A&E) 
Department of the Bahawal Victoria Hospital (BVH), Bahawalpur, Pakistan. Methods: 
A descriptive, non-experimental, retrospective and cross sectional study design was 
employed. A sample of 4,320 prescriptions (systematic random sampling) was drawn 
out of the total prescriptions written during January to December 2014. The standard 
World Health Organization/International Network for Rational Use of Drugs (WHO/
INRUD) prescribing indicators were used to enumerate prescribing practices of the 
physicians. Published ideal standards for each of the indicators were used to identify 
the irrational drug use. An additional indicator (the percentage share of each anti-
biotic) was also determined. Results: The average number of drugs per encounter 
was 2.3 (SD = 1.3) (optimal value = 1.6–1.8), the drugs prescribed by generic name 
were 83.1% (optimal value = 100%), the encounters with an antibiotic and injec-
tion prescribed were 52.4% (optimal value = 20.0–26.8%) and 98.0% (optimal value 
= 13.4–24.1%) respectively and the drugs prescribed from Essential Drugs List were 
81.5% (optimal value = 100%). Out of 52.4% (n = 2,262) prescriptions with antibiotics 
prescribed, 77.7% (n = 1758) had one antibiotic, 22.1% (n = 499) included two antibi-
otics, and only 0.2% (n = 5) had three antibiotics. Cephalosporins (81.5%), were the 
most commonly prescribed class of antibiotics followed by penicillins (6.4%) and 
fluoroquinolones (6.2%). Among the individual antibiotics, Ceftriaxone contributed 
the highest percentage share of 71.8% followed by cefotaxime (5.6%) and metronida-
zole (4.7%). The most frequently prescribed antibiotic combination was ciprofloxacin 
with metronidazole (52.1%). ConClusions: The irrational prescribing practices were 
common. Continuous education and training of the physicians is required to ensure 
rational prescribing of antibiotics and injections.
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objeCtives: The UK operates free pricing of new chemical entities (NCEs). The 
2014 PPRS was a radical departure from its predecessors, focussing on industry’s 
obligation to repay the Department of Health (DH) for growth in the NHS drug 
expenditure beyond certain limits. These repayments look set to exceed original 
estimates, reducing certainty for members of the voluntary scheme. The statutory 
regulations impose higher price cuts at the outset, ensuring those not in the PPRS 
do not have an advantage. As NHS sales from new NCEs launched after Jan 1st 2014 
are exempt from PPRS payment calculations, we show that the scheme favours 
those with products early in their life span. Methods: 15 case studies of small 
(n= 5), medium (n= 6) and large companies (n= 4) were reviewed to identify the 
implications for manufacturers with established portfolios compared to those with 
new launches after January 2014 under the PPRS and statutory scheme. We review 
legal options for companies who consider themselves unfairly treated. Results: 
Evidence exists of an imbalance in the PPRS impact, thus negatively affecting the 
UK as an early launch market. Companies have successfully challenged the appli-
cation of the statutory scheme price reductions to products already covered by a 
tender and the impact on international reference pricing. The scheme potentially 
amounts to an unlimited payment to the DH and worryingly payments are allo-
cated to an undefined pot rather than to the original budget holder. Price rises are 
possible, subject to justification on the basis of eight main factors. ConClusions: 
Companies supplying mainly mature products that offer the NHS good value for 
money are disproportionately affected compared with larger companies with a 
broader international portfolio, leading to an increase in price rise applications. 
Companies with a pipeline of NCEs, which are commonly more expensive, are the 
winners despite driving greater NHS expenditure.
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objeCtives: Heterogeneity in interpreting same clinical data of EMA approved 
medicines by HTA agencies of EU member states potentially delays accessibility 
